<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01427582</url>
  </required_header>
  <id_info>
    <org_study_id>05- EAP- STS</org_study_id>
    <nct_id>NCT01427582</nct_id>
  </id_info>
  <brief_title>YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access</brief_title>
  <official_title>YONDELIS(Trabectedin) Single Patient Compassionate Use / Expanded Access in Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <brief_summary>
    <textblock>
      The YONDELIS (trabectedin) Single Patient Compassionate Use /Expanded Access program provides&#xD;
      patients with advanced soft tissue sarcoma, who do not qualify for ongoing clinical trials&#xD;
      with YONDELIS (trabectedin), access to this investigational treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The single patient treatment instructions for use are intended for a single patient with&#xD;
      advanced soft tissue sarcoma. The patient will be treated with YONDELIS® (trabectedin) i.v.&#xD;
      formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days, provided that&#xD;
      he/she fulfills all eligibility criteria.&#xD;
&#xD;
      The patient may continue to receive therapy until there is evidence of disease progression or&#xD;
      unacceptable toxicity. Safety will be evaluated and serious adverse events will be reported.&#xD;
      Disease assessments will occur according to institutional practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Soft Tissue Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin</intervention_name>
    <description>Trabectedin i.v. formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days</description>
    <other_name>YONDELIS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent.&#xD;
&#xD;
          2. 18 years-of-age or older.&#xD;
&#xD;
          3. Unresectable, advanced or metastatic, histologically proven soft tissue sarcoma.&#xD;
&#xD;
          4. Recovery from toxic effects of prior therapies to NCI CTC Grade 1 or better.&#xD;
&#xD;
          5. Hematologic variables:&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL&#xD;
&#xD;
               -  ANC ≥1,500/μL&#xD;
&#xD;
               -  Platelet count ≥100,000/μL&#xD;
&#xD;
          6. Serum creatinine ≤ upper limit of normal (ULN)&#xD;
&#xD;
          7. Hepatic function variables:&#xD;
&#xD;
               -  Total bilirubin ≤ ULN&#xD;
&#xD;
               -  Total alkaline phosphatase ≤ ULN, or if &gt; ULN, then alkaline phosphatase liver&#xD;
                  fraction or 5'-nucleotidase must be ≤ ULN.&#xD;
&#xD;
               -  AST (serum aspartate transaminase [SGOT]) and ALT (serum alanine transaminase&#xD;
                  [SGPT]) must be ≤ 2.5xULN&#xD;
&#xD;
               -  Albumin ≥2.5 g/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breast-feeding women, or patients (male or female) not employing adequate&#xD;
             contraception. Acceptable means of birth control include IUD, oral contraceptive,&#xD;
             subdermal implant, and a condom with a contraceptive sponge or suppository.&#xD;
&#xD;
          2. Less than 4 weeks from last dose of systemic cytotoxic therapy, radiation therapy, or&#xD;
             therapy with any investigational agent&#xD;
&#xD;
          3. Active viral hepatitis or chronic liver disease&#xD;
&#xD;
          4. Unstable cardiac condition, including congestive heart failure or angina pectoris,&#xD;
             myocardial infarction within 1 year before enrollment, uncontrolled arterial&#xD;
             hypertension or arrhythmias&#xD;
&#xD;
          5. Active infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>John C. Bagwell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>August 30, 2011</study_first_submitted>
  <study_first_submitted_qc>August 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2011</study_first_posted>
  <last_update_submitted>August 30, 2011</last_update_submitted>
  <last_update_submitted_qc>August 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

